|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2011-3-1
|
|
pubmed:abstractText |
Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel inhibitor of Bcl-2 family proteins, was conducted to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with solid tumors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BonomiPhilipP,
pubmed-author:BusmanToddT,
pubmed-author:CamidgeD RossDR,
pubmed-author:ChiuYi-LinYL,
pubmed-author:DiveCarolineC,
pubmed-author:EnschedeSari HSH,
pubmed-author:GandaraDavidD,
pubmed-author:GandhiLeenaL,
pubmed-author:HannChristine LCL,
pubmed-author:HemkenPhilip MPM,
pubmed-author:HumerickhouseRodR,
pubmed-author:KhairaDivisD,
pubmed-author:KrivoshikAndrew PAP,
pubmed-author:LitvinovichElizabethE,
pubmed-author:McKeeganEvelyn MEM,
pubmed-author:NolanCathyC,
pubmed-author:Ribeiro de OliveiraMoacyrM,
pubmed-author:RudinCharles MCM,
pubmed-author:ShapiroGeoffrey IGI,
pubmed-author:XiongHaoH
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
909-16
|
|
pubmed:meshHeading |
pubmed-meshheading:21282543-Administration, Oral,
pubmed-meshheading:21282543-Aged,
pubmed-meshheading:21282543-Aged, 80 and over,
pubmed-meshheading:21282543-Aniline Compounds,
pubmed-meshheading:21282543-Dose-Response Relationship, Drug,
pubmed-meshheading:21282543-Drug Administration Schedule,
pubmed-meshheading:21282543-Female,
pubmed-meshheading:21282543-Genes, bcl-2,
pubmed-meshheading:21282543-Humans,
pubmed-meshheading:21282543-Male,
pubmed-meshheading:21282543-Maximum Tolerated Dose,
pubmed-meshheading:21282543-Middle Aged,
pubmed-meshheading:21282543-Neoplasms,
pubmed-meshheading:21282543-Prognosis,
pubmed-meshheading:21282543-Risk Assessment,
pubmed-meshheading:21282543-Small Cell Lung Carcinoma,
pubmed-meshheading:21282543-Sulfonamides,
pubmed-meshheading:21282543-Survival Analysis,
pubmed-meshheading:21282543-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
|
|
pubmed:affiliation |
Dana-Farber Cancer Institute, Boston, MA, USA. Leena_Gandhi@dfci.harvard.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
